Wegovy injection is FDA-approved for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis, consistent with stages F2–F3. It is used alongside a reduced-calorie diet and increased physical activity. If your scan says “fatty liver,” the next thing to find out is how your clinician describes the liver injury and scarring. The scan finding alone leaves both questions open. Wegovy U.S. prescribing information.
What does a report of fatty liver tell you?
Steatosis means fat has accumulated in the liver. When liver fat occurs with at least one cardiometabolic risk factor, the diagnosis may be MASLD, short for metabolic dysfunction-associated steatotic liver disease. MASH, or metabolic dysfunction-associated steatohepatitis, describes liver fat accompanied by inflammation and liver-cell injury. Older results may use NAFLD and NASH, the earlier names for related diagnoses. AASLD terminology guide.
Fibrosis is scarring. Its stage tells you something different from the amount of fat on a scan. F2 is moderate scarring, F3 is advanced scarring, and F4 is cirrhosis. Someone can have fat or even MASH with less scarring than the Wegovy indication specifies. Someone with cirrhosis needs care that accounts for that different stage of disease.
Which Wegovy treatment does the MASH indication cover?
The label requires three things for the liver indication: an adult with MASH, fibrosis consistent with F2 or F3, and no cirrhosis. It gives no separate obesity or type 2 diabetes requirement for MASH. For example, a person with MASH and F2 fibrosis can ask about the indication even if they do not meet the BMI criteria used for prescribing Wegovy for weight management. People with liver fat who receive it for weight may be receiving it under a separate indication.
The liver indication is for the injection, with a usual maintenance dose of 2.4 mg once weekly. The label allows 1.7 mg weekly if 2.4 mg is not tolerated. Wegovy tablets and the 7.2 mg injection have different labeled uses. Read the condition, formulation, and dose together when comparing prescriptions or research results. Wegovy prescribing information, sections 1 and 2.2.
What did the biopsies show after 72 weeks?
ESSENCE randomized people with biopsy-defined MASH and F2–F3 fibrosis to weekly semaglutide injection, targeting 2.4 mg, or placebo. Both groups also received lifestyle counseling and standard care for other cardiometabolic conditions. The planned interim analysis included the first 800 participants. Original ESSENCE report.
| Biopsy outcome at week 72 | Semaglutide | Placebo |
|---|---|---|
| MASH resolved and fibrosis did not worsen | 62.9% | 34.3% |
| Fibrosis improved by at least one stage and MASH did not worsen | 36.8% | 22.4% |
| MASH resolved and fibrosis improved | 32.7% | 16.1% |
Read the first two rows as separate questions. For the first, inflammation and cell injury improved enough to meet the study definition of resolution, and scarring could stay at the same stage. For the second, scarring improved by at least one stage, and MASH could still be present. The third row shows the overlap: about 33 in 100 people in the semaglutide group achieved both, compared with about 16 in 100 on placebo. Each percentage describes the share of people who met a criterion, and none describes the amount of scar tissue removed from one person's liver.
What does accelerated approval still leave to measure?
The FDA based accelerated approval on improvement in MASH and fibrosis, using those biopsy results as surrogate endpoints. They are measured changes in the liver that may predict longer-term health benefits. The confirmatory portion of ESSENCE is designed to assess clinical outcomes over a longer period. The 72-week results alone cannot tell us how often treatment prevents liver failure, transplantation, or death. Continued approval may depend on confirmation of clinical benefit. FDA MASH approval explanation.
What should you ask if your scan only mentions liver fat?
Start with the result you have. If the report is from a routine ultrasound, ask how your clinician plans to assess the risk of scarring. A blood-based risk score such as FIB-4 can help decide whether further assessment is needed. Specialized imaging such as elastography measures liver stiffness and can help assess fibrosis. A biopsy directly examines liver tissue, and clinical care often starts with noninvasive tests even though ESSENCE used biopsy to define its study population. NIDDK diagnosis guide.
If you already have an estimated stage, bring the report and ask which result supports it and whether there is any concern for cirrhosis. If you discuss treatment, ask how your team would follow the liver disease alongside any changes in weight or liver enzymes. Those changes can be worth measuring without resolving the question of how the scarring itself is doing.

About the author
Maya Lee
Glowise Senior GLP-1 Content Editor
Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.
She helps readers ask better questions and keep the details relevant to a care conversation together.
See more Glowise on Google
Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.



